Investor Presentaiton

Potential new treatment option for HER2 expressing ENHERTU® Solid tumors DESTINY-PanTumor02 study (ASCO 2023) Demonstrated clinically meaningful activity across a broad range of HER2 expressing solid tumors (2L+) 100 90 80 75.0 84.6 Objective Response Rate by HER2 status 70 60 50.0 50 40.0 Confirmed ORR, % 40 30 20 20 28 57.5 63.6 56.3 47.1 45.0 36.8 10 All IHC 3+ IHC 2+ All IHC 3+ IHC 2+ All IHC 3+ IHC 2+ All IHC 3+ 22.0 IHC 2+ All IHC 3+ IHC 2+ 4.0 5.3 0.0 0.0 0 n= 40 8 20 Cervical 40 13 17 Endometrial 40 11 19 Ovarian 41 16 14 BTC 25 2 19 Pancreatic 41 56.3 39.0 35.0 30.0 18.8 All IHC 3+ IHC 2+ All 61.3 44.4 37.1 27.2 IHC 3+ IHC 2+00 All IHC 3+ IHC 2+ 16 20 Bladder 40 9 16 Othera 267 75 125 Total Median DOR, months (95% CI) All patients (N=99) 11.8 (9.8-NE) ■ORR: 37.1% in all patients (n=267) and 61.3% in patients with IHC 3+ (n=75) IHC 3+ (n=46) 22.1 (9.3-NE) IHC 2+ (n=34) 9.8 (4.2-12.6) ■DOR: median DoR 11.8 months in all patients responded (n=99) and 22.1 months in patients with IHC 3+ (n=46) ■Most common adverse events of ENHERTUⓇ in this study were neutropenia, anemia, fatigue, nausea, thrombocytopenia which were comparable to the known profile seen with T-DXd Majority of ILD/pneumonitis events were grade 1 or 2; one grade 3 event and one grade 5 event were observed a Analysis of DoR was performed in patients with objective response b Responses in extramammary Paget's disease, head and neck cancer, oropharyngeal neoplasm, and salivary gland cancer. BTC: biliary tract cancer, Cl: confidence interval, DoR: duration of response, IHC: immunohistochemistry, ILD: interstitial lung disease, NE: non-estimable; ORR, objective response rate. 19 Daiichi-Sankyo

View entire presentation